Innovative Approach Targets Glioblastoma’s Ecosystem

A research team has developed an experimental therapy for glioblastoma, a deadly form of brain cancer, utilizing an approach that targets the disease’s critical weaknesses. Although intended for future patients, the therapy has only been tested in preclinical models. The findings published in Nature have garnered attention for differing from previous efforts.

The urgency for new treatments is evident. Glioblastoma is highly lethal, with patient survival averaging 12 to 18 months post-diagnosis. Long-term survival is rare, with only about 5 percent living beyond five years. Researchers believe traditional views of glioblastoma contribute to the problem.

“Solid tumours like glioblastoma are not just a mass of cancerous cells; they are an ecosystem of cancerous + non-cancerous cells that grow and support each other,”

said Shan Grewal, a doctoral candidate at McMaster University and co-lead author of the study. This perspective heavily influenced their research strategy. According to Grewal, solely focusing on cancer cells overlooks important biological processes crucial for disease survival.

The team concentrated on a protein called GPNMB found on both glioblastoma cells and macrophages, immune cells linked to the tumor. This discovery led to engineering CAR-T cells to identify GPNMB, creating treatment that attacks multiple disease components simultaneously.

“We identified GPNMB as a protein found on both glioblastoma cells and tumour-supporting macrophages, allowing us to use a CAR-T cell strategy that can attack glioblastoma on two fronts at once,”

Grewal explained. The strategy aims to treat glioblastoma as an interconnected tumor-immune ecosystem rather than isolated cancer cells.

In preclinical models, the therapy eliminated tumors and resulted in long-term disease-free survival, including in models from patient tumors. The findings revealed insights into cancer biology, particularly GPNMB’s role in both cancerous and associated macrophages.

“Many hoped immunotherapy could change outcomes for GBM patients, but long-term success has been elusive,”

Grewal stated, noting the tumor’s ability to create a suppressive environment. Senior author Sheila Singh of McMaster University emphasized treating the tumor and the environment it thrives in.

Despite promising results, challenges remain. The therapy is yet to be tested in clinical trials. Researchers must determine patient suitability, treatment delivery methods, and complete safety evaluations. Grewal noted the work is an early-stage advance, offering hope but not yet available.

“Glioblastoma remains one of the most devastating cancers, and patients deserve new options,”

Grewal said, emphasizing the importance of continued research.